Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics

@article{Marcucci2005MolecularHA,
  title={Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics},
  author={Guido Marcucci and Krzysztof Mr{\'o}zek and Clara Derber Bloomfield},
  journal={Current Opinion in Hematology},
  year={2005},
  volume={12},
  pages={68-75}
}
Purpose of reviewPatients with acute myeloid leukemia (AML) and normal karyotype constitute the single largest cytogenetic group of AML, estimated to account for 45% of adults with de novo AML. This article critically reviews the recent literature that addresses the molecular heterogeneity of this group of patients and how this relates to prognostic stratification and novel therapeutic approaches. Recent findingsFour prognostic biomarkers-the internal tandem duplication and point mutations in… 
Molecular genetics in acute myeloid leukemia
TLDR
Targeted therapy studies with FLT3 inhibitors for patients withFLT3-mutated AML as single agents or combined with chemotherapy illustrate the translation of the molecular techniques into clinical practice already being realized in distinct subgroups of AML.
Distinct gene mutations, their prognostic relevance and molecularly targeted therapies in Acute Myeloid Leukemia (AML)
TLDR
The identified gene mutations, mainly targetable lesions are gain of function mutations of JAK2 and cKIT and FLT3 in APL have been associated with clinical features and/ or outcome of patients with these AML subtypes and emphasize the significance of genetic testing for common translocations.
Molecular determinants of prognosis in acute myeloid leukemia (AML) with normal karyotype
TLDR
The molecular subclassification of the normal karyotype group provides the basis for more differentiated therapeutic approaches which target specific genetic alterations in the normalKaryotype AML.
Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances
TLDR
The discovery of new prognostic markers has increased the understanding of leukemogenesis and may lead to improved prognostication and generation of novel risk-adapted therapies.
Incidence and Prognostic Value of NPM1 and FLT3 Gene Mutations in AML with Normal Karyotype
TLDR
NPM1 gene mutation was detected among 34 patients (47.9%) and was associated with a high white blood cell count, involvement of the monocytic lineage, CD34 negativity, and high frequency of FLT3ITD.
Is it important to decipher the heterogeneity of "normal karyotype AML"?
  • S. Nimer
  • Biology
    Best practice & research. Clinical haematology
  • 2008
Molecular genetic pathways as therapeutic targets in acute myeloid leukemia.
  • T. Haferlach
  • Biology
    Hematology. American Society of Hematology. Education Program
  • 2008
TLDR
This review provides an overview on the most relevant genetic markers, which serve as basis for targeted therapy approaches now or might represent options for such approaches in the future, and summarizes recent results of targeted therapy studies.
BAALC and ERG expression in acute myeloid leukemia with normal karyotype: impact on prognosis
TLDR
Overexpression of BAALC and ERG either separate or concomitant predict adverse clinical outcome and may define important risk factor in cytogenetically normal AML.
Genetic profiling in acute myeloid leukemia: a path to predicting treatment outcome
TLDR
The authors believe that a combination of genetic, epigenetic and transcriptional data will represent, in the future, the molecular basis for treatment decision with the highest predictive potential.
Molecular diagnostics in acute leukemias
TLDR
This review summarizes the most important recurrent molecular markers seen in acute leukemias, their role in prognosis and therapy and provides an overview on the relevant PCR techniques.
...
...

References

SHOWING 1-10 OF 72 REFERENCES
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia.
TLDR
The use of gene-expression profiling improves the molecular classification of adult AML and identifies new molecular subtypes of AML, including two prognostically relevant subgroups in AML with a normal karyotype.
CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.
  • S. Fröhling, R. Schlenk, K. Döhner
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
Mutant CEBPA predicts favorable prognosis and may improve risk stratification in AML patients with normal cytogenetics, suggesting thatCEBPA loss-of-function mutations define a distinct biologic subclass of AML withnormal cytogenomics.
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.
To assess the prognostic relevance of activating mutations of the FLT3 gene in homogeneously treated adults 16 to 60 years of age with acute myeloid leukemia (AML) and normal cytogenetics,
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
TLDR
Besides the importance of FLT3-LM for biologic and clinical characterization of AML, its value as a marker for disease monitoring based on 120 follow-up samples of 34 patients is shown.
Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells
TLDR
In conclusion, immunophenotyping may be a suitable approach to investigating MRD status in AML patients with PTD of the MLL gene.
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.
TLDR
It is concluded that high BAALC expression predicts an adverse prognosis and may define an important risk factor in AML with normal cytogenetics.
Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics.
TLDR
The partial tandem duplication of ALL1 was responsible for ALL1 rearrangement in all such cases examined, making it a frequent molecular defect in adult AML patients with normal cytogenetics and thus require new therapeutic approaches.
Gene expression profiling of pediatric acute myelogenous leukemia.
TLDR
Surprisingly, AMLs containing partial tandem duplications of MLL failed to cluster with MLL chimeric fusion gene cases, suggesting a significant difference in their underlying mechanism of transformation.
Analysis of FLT 3 length mutations in 1003 patients with acute myeloid leukemia : correlation to cytogenetics , FAB subtype , and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
TLDR
Besides the importance of FLT3-LM for biologic and clinical characterization of AML, its value as a marker for disease monitoring based on 120 follow-up samples of 34 patients is shown.
...
...